2 Billion Dollar Verdict Sought In Actos Trial

LAS VEGAS, Aug. 27, 2015 /PRNewswire/ -- The nation's newest Actos trial gets underway Thursday, August 27^th in a Las Vegas courtroom.  Attorneys representing two southern Nevada patients will argue the men suffered severe effects, including death, after using the diabetes drug Actos.

"Takeda Pharmaceuticals withheld from our clients what they as a company knew, that their drug Actos caused an increased risk of bladder cancer," said attorney Robert Eglet.  "In order to hold Takeda responsible it is appropriate to seek substantial punitive damages."

Attorneys from Eglet Prince and Kemp, Jones & Coulthard law firms represent the widow of Maurice J. Iorio who died from bladder cancer complications November 25, 2013 and George Decou who is suffering from bladder cancer.

"Not only did Takeda conceal what the company knew about their dangerous drug, they destroyed evidence on a massive scale in an attempt to avoid responsibility," said Eglet.

The latest Actos trial is one of many against Takeda Pharmaceuticals, a multi-billion dollar corporation headquartered in Japan.  Last year a Louisiana jury awarded a 9 Billion Dollar verdict in an Actos trial.  In a different trial in Las Vegas last year, a jury did not find Takeda responsible for causing bladder cancer in two southern Nevada women. 

Currently, Takeda is looking to establish a settlement with an estimated 8 thousand plaintiffs across the country who believe Actos caused their bladder cancer.

"It's important that our clients receive compensation from a jury," added Robert Eglet.  "Without substantial punitive damages there is nothing to deter a company of this size from engaging in the same unconscionable, deadly practices again."

Opening Statements begin at 10 am PST in Judge Jerry Wiese courtroom, Las Vegas District Court.

CONTACT: Tom Letizia, 702-545-8777, [email protected]

SOURCE Eglet Prince

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED